GEHC Stock Analysis — GE Healthcare
Sector: Healthcare
AI Verdict
GEHC trades at 12.5x next year's earnings, which is cheap for the 25.2% growth expected, and the moat from hospital integration makes that growth more credible than most.
Competitive Moat
GE Healthcare dominates in medical imaging and diagnostics, leveraging decades of proprietary hardware, embedded software, and service contracts that create high switching costs for hospitals. Its installed base and integration with hospital IT systems make it difficult for competitors to displace existing GEHC equipment.
Summary
GEHC trades at just 12.5x next year's earnings while analysts expect a 25.2% jump in EPS, making it a rare value in healthcare equipment.
Where It Stands
With a 1-year return of -14.23%, an RSI of 52.8 (neutral), and a forward P/E of 12.5x versus the sector median of 22x, GEHC is priced well below typical healthcare peers despite positive earnings momentum.
Key Metrics
- RSI: 52.8 — Neutral
- Trailing P/E: 15.6x
- Forward P/E: 12.5x
- PEG Ratio: 0.64
- Earnings Growth: +0.3%
- Revenue Growth: +0.1%
- Dividend Yield: 0.00%
- 1-Year Return: -14.23%
- 52-Week High: $89.77
- 52-Week Low: $58.75
Analyst Consensus
18 Buy · 9 Hold · 0 Sell (27 analysts)
Bull Case
Forward EPS growth of 25.2% against a forward P/E of 12.5x means you're paying a low price for substantial earnings expansion.
Bear Case
If GEHC's P/E reverts to 10x (closer to deep value territory), the stock could lose another 20% even if earnings meet expectations.
Catalyst to Watch
Quarterly earnings beats or misses—especially on imaging equipment orders—will determine if the expected 25.2% EPS growth is realistic.